Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
InSilico Medicine Cayman TopCo (FRA:O15) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
InSilico Medicine Cayman TopCo's EV-to-EBIT for today is
InSilico Medicine Cayman TopCo's current Enterprise Value is €2,595.21 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. InSilico Medicine Cayman TopCo's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-300.90 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
InSilico Medicine Cayman TopCo's EV-to-EBITDA for today is:
InSilico Medicine Cayman TopCo's current Enterprise Value is €2,595.21 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. InSilico Medicine Cayman TopCo's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-296.79 Mil.
InSilico Medicine Cayman TopCo's current Enterprise Value is €2,595.21 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. InSilico Medicine Cayman TopCo's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €48.39 Mil.
InSilico Medicine Cayman TopCo's current Enterprise Value is €2,595.21 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. InSilico Medicine Cayman TopCo's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-66.04 Mil.
InSilico Medicine Cayman TopCo's current Enterprise Value is €2,595.21 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. InSilico Medicine Cayman TopCo's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-68.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo Enterprise Value Related Terms
InSilico Medicine Cayman TopCo Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo Enterprise Value Chart
FRA:O15 vs MSFT, ORCL, PLTR: Enterprise Value Comparison
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo Enterprise Value vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's Enterprise Value distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's Enterprise Value falls into.
InSilico Medicine Cayman TopCo Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of €2,595.21 Mil mean?
InSilico Medicine Cayman TopCo (FRA:O15) has a Enterprise Value of €2,595.21 Mil as of Aug. 27, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on InSilico Medicine Cayman TopCo and its competitors.
Is InSilico Medicine Cayman TopCo's Enterprise Value too high?
InSilico Medicine Cayman TopCo's current Enterprise Value is €2,595.21 Mil. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Enterprise Value compare to MSFT and ORCL?
InSilico Medicine Cayman TopCo's Enterprise Value of €2,595.21 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Software company?
A good Enterprise Value depends on the Software industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on InSilico Medicine Cayman TopCo and its competitors. InSilico Medicine Cayman TopCo's current Enterprise Value is €2,595.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current Enterprise Value of €2,595.21 Mil. The current Enterprise Value is €2,595.21 Mil. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current Enterprise Value is €2,595.21 Mil as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score
Get the complete analysis for FRA:O15
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O15 has been successfully added to your 
